Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

-on therapy to a sulfonylurea when the single agent alone does not provide adequate glycemic control and as add-on therapy to the combination of a sulfonylurea plus metformin when dual therapy does not provide adequate glycemic control. The FDA is reviewing the sNDA for these indications and Merck expects FDA action by mid-October.

A pooled analysis of 5,141 patients showed overall incidence of adverse experiences, incidence of serious adverse experiences, and incidence of discontinuations due to adverse experiences were similar in the JANUVIA and non-exposed groups for up to two years (Poster #534-P)

The safety and tolerability of JANUVIA was assessed by pooling data from nine completed Phase IIB and III studies, including the studies discussed above, ranging from 24 to 104 weeks in duration, and including 5,141 patients treated with either JANUVIA 100 mg daily (n=2,786) or other treatments (placebo or an active comparator) (n=2,355). The studies assessed JANUVIA as monotherapy, initial combination therapy with metformin, or add-on to another oral agent (metformin, pioglitazone, sulfonylurea, or sulfonylurea and metformin).

JANUVIA 100 mg daily was generally well-tolerated as monotherapy, as initial combination therapy, or as add-on therapy. For adverse experiences (either clinical or laboratory), the overall incidence of adverse experiences, the incidence of serious adverse experiences, and the incidence of discontinuations due to adverse experiences were similar in the JANUVIA treated patients and in patients who received other therapies (patients on placebo or active comparator). Drug-related adverse experiences were higher in the non-exposed group due to hypoglycemia reported in sulfonylurea-treated patients (since studies in which a sulfonylurea agent was a treatment in patients not receiving JANUVIA were included in this pooled analysis).

Specific clinical adverse experiences, expressed as a rate of greater than or equal to 1 event
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/21/2013)... May 21, 2013 Reaching a critical milestone ... National Association of Boards of Pharmacy ® (NABP ... domain suffix has passed the Internet Corporation for Assigned ... launch the .PHARMACY gTLD by the end of 2013, ... online pharmacies and related entities that are located in ...
(Date:5/21/2013)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China and the parent of Chang,an Hospital, today reported ... ended March 31, 2013 [1] . First ... consists of net revenues generated from the network business ...
(Date:5/21/2013)... LAWRENCE, Mass. , May 21, 2013  NxStage ... manufacturer of innovative dialysis products, today announced that it ... home, critical care and in-center products to DaVita, the ... (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) For the ... the United States , NxStage has executed a ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13NxStage Announces New Agreements with DaVita 2
... Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announced ... from a randomized Phase 2 clinical trial of,OGX-011 ... arm"),compared to docetaxel and prednisone alone ("the control ... cancer. The current 10.6,month median overall survival ...
... DIEGO, Dec. 3 Vical Incorporated,(Nasdaq: VICL ... with EIP,Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and ... and the Turkish,Republic of Northern Cyprus. EIP has agreed ... to pay Vical upfront and milestone payments,plus a specified ...
Cached Medicine Technology:Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... Colo. (May 21, 2013) A paper recently published ... and co-written by physicians and scientists at the University ... genetic risk factor for pulmonary fibrosis can be used ... disease. , Researchers looked at a fairly common variant ... a component of the mucous produced by the bronchial ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 21, 2013 While North Carolina is ... comprehensive travel guides. Brunswick Plantation & Golf Resort is ... include access to 27 holes of "Top10" championship golf. ... North Carolina, knowing the Top 10 from ... away the overwhelming task of selecting the course to ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... Medicine at Harvard Medical School and Beth Israel Deaconess ... Lectureship at the annual meeting of the Federation of ... month in Washington, DC. Named in honor of ... for radioimmunoassay led to discoveries that have helped to ...
... By Maureen Salamon HealthDay Reporter , THURSDAY, ... N.C., was in her early forties when she developed anorexia ... "In the middle of a disorder like that, you ... you," she said. Luckily, Hodgin sought the care of ...
... people develop diabetes because they don,t have enough pancreatic beta ... sugar levels. But what if other cells ... cells? Could we potentially cure diabetes? Researchers ... an important step in that direction. They report in the ...
... PHILADELPHIA Black cardiac arrest victims are more likely ... a large black population than when they,re brought to hospitals ... research from the University of Pennsylvania School of Medicine. The ... American Heart Journal . The Penn team found that, ...
... Tierney, M.D., president and CEO of the Regenstrief Institute ... Indiana University School of Medicine, received a 2011 Distinguished ... and Education Meeting on April 28 in Washington, DC. ... Achievement and Contribution to Clinical and Translational Science. He ...
... Vision and Ophthalmology (ARVO) is pleased to announce its 2011 ... the ARVO 2011 Annual Meeting, May 1 5, in ... MD, PhD, FARVO, Mildred Weisenfeld Award for Excellence in Ophthalmology: ... James T. Rosenbaum, MD, FARVO, Cogan Award: Andrew J. Fischer, ...
Cached Medicine News:Health News:Christos Mantzoros honored by Federation of the American Societies for Experimental Biology 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 3Health News:Researchers discover mechanism that could convert certain cells into insulin-making cells 2Health News:Black cardiac arrest patients more likely to be admitted to hospitals with lowest survival rates 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:2011 ARVO Award recipients honored at annual meeting 2Health News:2011 ARVO Award recipients honored at annual meeting 3
... The BiPAP Pro with Bi-Flex bi-level ... time that the BiPAP Pro takes to ... includes Digital Auto-Trak Sensitivity™ which automatically triggers ... expiratory pressures based on the patients breathing ...
... Gradient Lipoprotein Electrophoresis System (PGGE) is ... as low density lipoproteins (LDL) and ... particle size using nondenaturing pore gradient ... PAGE and short DNA sequencing runs. ...
... The Lipoprint System is a high resolution ... routinely tested by other methods. The test procedure ... than three hours. Any abnormal value is clearly ... the highly atherogenic, small dense LDL in red ...
... This control monitors spinal fluid analyte methods ... Fluid Control is packaged in dropper-tip bottles ... the need for pipets and minimizing waste. ... most major chemistry analyzers and nephelometers: Abbott ...
Medicine Products: